Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Colony Capital, Sorrento Therapeutics, Carnival Corporation, and Wells Fargo and Encourages Investors to Contact the Firm
July 15, 2020 15:00 ET
|
Bragar Eagel & Squire
NEW YORK, July 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sorrento Therapeutics, Carnival Corporation, Wells Fargo, and Hebron Technology and Encourages Investors to Contact the Firm
July 08, 2020 16:00 ET
|
Bragar Eagel & Squire
NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hamilton Beach Brands, Colony Capital, Sorrento Therapeutics, and Carnival Corporation and Encourages Investors to Contact the Firm
July 01, 2020 16:00 ET
|
Bragar Eagel & Squire
NEW YORK, July 01, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sorrento Therapeutics, Carnival Corporation, Wells Fargo, and Hebron Technology and Encourages Investors to Contact the Firm
June 24, 2020 18:00 ET
|
Bragar Eagel & Squire
NEW YORK, June 24, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hamilton Beach Brands, Colony Capital, Sorrento Therapeutics, and Carnival Corporation and Encourages Investors to Contact the Firm
June 17, 2020 17:00 ET
|
Bragar Eagel & Squire
NEW YORK, June 17, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CytomX, Hamilton Beach Brands, Colony Capital, and Sorrento Therapeutics and Encourages Investors to Contact the Firm
June 10, 2020 16:00 ET
|
Bragar Eagel & Squire
NEW YORK, June 10, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hamilton Beach Brands, Colony Capital, Sorrento Therapeutics, and Carnival Corporation and Encourages Investors to Contact the Firm
June 03, 2020 19:00 ET
|
Bragar Eagel & Squire
NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...
SORRENTO DEVELOPS STI-4398 (COVIDTRAP™ PROTEIN) FOR POTENTIAL PREVENTION AND TREATMENT OF SARS-COV-2 CORONAVIRUS DISEASE (COVID-19)
March 20, 2020 07:00 ET
|
Sorrento Therapeutics, Inc.
COVIDTRAPTM is a proprietary ACE2-Fc protein that binds to the S1 domain of the spike protein of the SARS-CoV-2 virus;COVIDTRAP is designed to block the SARS-CoV-2 virus from binding and infecting...
Sorrento Announces Dr. Robin Smith as New Member of the Board of Directors
December 16, 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that Robin L. Smith, MD, MBA has been appointed to its Board of Directors. Dr....
Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering
October 09, 2019 10:35 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn...